NCT04235933View on ClinicalTrials.gov

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Healthy
Interventions
BIOLOGICAL

Tai Ai(RC18) 80mg

The patient received one treatment of RC18 80mg in the test group

BIOLOGICAL

Tai Ai(RC18) 160mg

The patient received one treatment of RC18 160mg in the test group

BIOLOGICAL

RC18 240mg

The patient received one treatment of RC18 240mg in the test group

Trial Locations (1)

264006

Remegen，ltd., Yantai

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04235933 - A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects | Biotech Hunter | Biotech Hunter